TITLE:
Clinical Efficacy of Prolonged First-Line Treatment against Helicobacter pylori in Ouagadougou
AUTHORS:
Nômawendé Inès Compaore, Couna Christiane Some, Nanelin Alice Guingane, Tegwinde Rebeca Compaore, Marie Nina Compaore, Roger Sombie, Alain Bougouma
KEYWORDS:
Helicobacter pylori, Treatment Efficacy, Triple Therapies, Quadritherapy
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.12 No.7,
July
27,
2022
ABSTRACT: Background: Helicobacter pylori (H. pylori) infection is a public health concern. In fact, due to bacterial resistance, treatment strategy is a challenge. It is then more recommended to prolong first-line treatment. In order to be acceptable, the clinical efficacy of treatment must be higher than 90%. Aim: We aimed to assess the outcome of prolonged first-line treatment among adults. Patients and Methods: The study was cross-sectional among adults and patients were treated for H. pylori eradication for the first time during 10 to 14 days. Recruitment was made from March 2019 in six private polyclinics and two hospitals of the city of Ouagadougou. We used monoclonal antigen (Ag) test on the stool samples for diagnostic and for the patients follow up. Chi squared (X2) tests and ANOVA for the comparison of percentages and means were determined using with STATA®software program in the bilateral 95% confidence interval for the statistical analysis. Results: In the different medical centers for 19 months, 365 patients were compiled. The sex-ratio was 0.64. The average age was 43.55 years. The treatment efficacy was 92.88%. Treatment efficacy was better with p-value -3 depending on prescriber: gastroenterologist (94.07%), general practitioner (75%); compliance before treatment: excellent (95.88%) or bad (50%); number of consultations: ≥four (94.35%), three (96.32%), two (78.85%). Triple therapies efficacy was 90.81%; p = 0.19. Quadritherapy efficacy was 95%; p = 0.5. Conclusion: This research is a contribution to the advent of national or African recommendations.